Venous thrombosis causes an estimated 50,000 deaths per year in the US and has an incidence of 1 per 1000 annually. There are many reported risk factors including a genetic element that can contribute to thrombosis. Cardiovascular disease is a leading cause of death for both men and women in most racial ethnic groups.
.
|
TRP
The Elucigene TRP (Thrombosis Risk Panel) provides laboratories with a simple and accurate means of routinely testing for the three most relevant mutations implicated in the risk of developing venous thromboembolism.
The factor V Leiden (R506Q) mutation is the most common inherited form of thrombophilia, but the Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T also contribute toward increased risk.
• How to Order • Cat. No. TH003B2
|
| TRP Downloads |
| Information sheet |
|
|
| Safety sheet |
|
|
| Instructions for use |
|
|
|
|
TRP w/o MTHFR
As ELUCIGENE TRP (Thrombosis Risk Panel) but does not include detection of the C677T MTHFR polymorphism.
• How to Order • Cat. No. TH002B2
NOTE: Elucigene TRP is also offered as a fluorescent based assay (THF03B2) for analysis of factor V Leiden (R506Q), Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T on Applied Biosystems 3*** series instruments. See the Elucigene TRP-F section of this website for further details.
Please note: Licences for the in vitro diagnostic analysis of gene mutations detected by these reagents may be required and are the responsibility of the reagent purchaser
